BamSEC and AlphaSense Join Forces
Learn More

SAB Biotherapeutics Inc. – Material Contracts

NASDAQ: SABS    
Share price (7/6/26): $3.92    
Market cap (7/6/26): $300 million

Material Contracts Filter

EX-10.2
from 10-Q 4 pages First Amendment to Lease Agreement
12/34/56
EX-10.1
from 8-K 21 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential Master Manufacturing Services Agreement
12/34/56
EX-10.1
from 8-K 22 pages SAB Biotherapeutics, Inc. 2021 Omnibus Equity Incentive Plan, as Amended (Amended August 14, 2025) Article 1 Effective Date, Objectives and Duration
12/34/56
EX-10.4
from 8-K 5 pages Board Designation Side Letter Agreement
12/34/56
EX-10.3
from 8-K 5 pages Support Agreement
12/34/56
EX-10.2
from 8-K 23 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 48 pages Securities Purchase Agreement
12/34/56
EX-10.4
from 10-K 17 pages Indemnification Agreement
12/34/56
EX-10.1
from 8-K 18 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential Lease Agreement
12/34/56
EX-10.2
from 10-Q 23 pages SAB Biotherapeutics, Inc. 2021 Omnibus Equity Incentive Plan, as Amended (Amended June 27, 2024) Article 1 Effective Date, Objectives and Duration
12/34/56
EX-10.1
from 8-K 19 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 3 pages November 6, 2023 via Email: Mark W. Conley MWCONLEY1@VERIZON.NET Dear Mr. Conley: SAB Biotherapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment on the Following Terms
12/34/56
EX-10.2
from 8-K 21 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 21 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 19 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 68 pages Securities Purchase Agreement
12/34/56
EX-10.5
from 10-K 10 pages Employment Agreement This Employment Agreement (The “Agreement”) Is Dated May 20, 2022 and Effective as of June 6, 2022 (The “Effective Date”), by and Between SAB Biotherapeutics, Inc., a Delaware Corporation (The “Company”), and Alexandra Kropotova (The “Employee”). Whereas, the Company Desires That the Employee Joins the Company to Serve in the Capacity of Executive Vice President-Chief Medical Officer of the Company, and the Employee Has Agreed to Serve in Such Position in Accordance With the Terms and Conditions of This Agreement; Now, Therefore, in Consideration of the Premises and Mutual Covenants Contained Herein, and for Other Valuable Consideration, the Company and the Employee Hereby Agree as Follows: 1. Certain Definitions. the Following Terms, as Used Herein, Have the Following Meanings
12/34/56
EX-10.1
from 8-K 42 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 6 pages Right of First Refusal Agreement
12/34/56
EX-10.1
from 8-K 7 pages Manufacturing Option Agreement
12/34/56